Soligenix (SNGX) versus Mirati Therapeutics (MRTX) Head to Head Contrast
Soligenix (NASDAQ: SNGX) and Mirati Therapeutics (NASDAQ:MRTX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, dividends, valuation and analyst recommendations.
This table compares Soligenix and Mirati Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current recommendations and price targets for Soligenix and Mirati Therapeutics, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Soligenix currently has a consensus price target of $5.25, indicating a potential upside of 167.86%. Mirati Therapeutics has a consensus price target of $13.71, indicating a potential downside of 22.95%. Given Soligenix’s stronger consensus rating and higher possible upside, analysts clearly believe Soligenix is more favorable than Mirati Therapeutics.
Institutional and Insider Ownership
2.1% of Soligenix shares are held by institutional investors. Comparatively, 64.7% of Mirati Therapeutics shares are held by institutional investors. 5.0% of Soligenix shares are held by company insiders. Comparatively, 5.1% of Mirati Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Earnings & Valuation
This table compares Soligenix and Mirati Therapeutics’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Soligenix||$10.45 million||1.64||-$3.24 million||($1.01)||-1.94|
|Mirati Therapeutics||N/A||N/A||-$83.11 million||($3.11)||-5.72|
Soligenix has higher revenue and earnings than Mirati Therapeutics. Mirati Therapeutics is trading at a lower price-to-earnings ratio than Soligenix, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Soligenix has a beta of 2.18, suggesting that its stock price is 118% more volatile than the S&P 500. Comparatively, Mirati Therapeutics has a beta of 1.61, suggesting that its stock price is 61% more volatile than the S&P 500.
Soligenix beats Mirati Therapeutics on 7 of the 12 factors compared between the two stocks.
Soligenix, Inc. is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, and its innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer. Its Vaccines/BioDefense business segment includes active development programs for RiVax, its ricin toxin vaccine candidate, OrbeShield, its GI acute radiation syndrome (GI ARS) therapeutic candidate, and SGX943, its melioidosis therapeutic candidate.
About Mirati Therapeutics
Mirati Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The companys clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors. Its clinical stage product candidates also comprise sitravatinib, an orally-bioavailable, potent, small molecule spectrum-selective kinase inhibitor, which is in Phase II clinical trials for the treatment of solid tumors, such as NSCLC and metastatic Renal Cell Carcinoma, as well as in Phase Ib clinical trials to treat NSCLC patients with RET, CHR4q12, CBL, and AXL genetic alterations; and mocetinostat, an orally administered spectrum-selective Class 1 histone deacetylase inhibitor, which is in Phase Ib/II clinical trials in combination with durvalumab for the treatment of patients with NSCLC. The company has a collaboration agreement with Foundation Medicine, Inc. and Guardant Health, Inc. to explore development of their platforms as companion diagnostics for glesatinib. Mirati Therapeutics, Inc. is headquartered in San Diego, California.
Receive News & Ratings for Soligenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix and related companies with MarketBeat.com's FREE daily email newsletter.